Abstract

Canonical Notch signaling is initiated by γ-secretase-mediated cleavage of the Notch receptor, leading to the release of the active intra-cellular domain of Notch that migrates to the nucleus and interacts with RBP-Jκ, resulting in the activation of downstream target genes. While canonical Notch signaling is well known to play an active role in several steps during development as well in multiple cell fate decisions, recent evidence from both invertebrate and vertebrate systems indicates that non-canonical, RBP-Jκ-independent signaling is important in several cellular processes including oncogenesis and activation of T lymphocytes. These observations raise the possibility that, through an understanding of non-canonical Notch signaling, novel strategies for inhibiting Notch signaling may prove useful in the design of therapies targeted to block aberrant Notch activity. In this mini-review, we will examine the current data demonstrating a non-canonical role for Notch signaling in both cancer and the immune system and suggest a better understanding of non-canonical signaling may reveal novel strategies to block Notch signaling in disease.

Highlights

  • Notch is a trans-membrane protein with four family members (Notch 1–4)

  • SUMMARY AND FUTURE PERSPECTIVES Notch signaling plays an important role in the fine tuning of oncogenesis and immunity as well as many other essential biological processes

  • We provide evidence for three types of non-canonical Notch signaling: (i) γ-secretase regulated activation of the Notch pathway that occurs independently of ligand interaction; (ii) Notch intra-cellular domain (NICD) activity independent of RBPJκ/CSL; (iii) membrane bound Notch signaling in the absence of cleavage by the γ-secretase complex and, in some cases, independent of ligand interaction (Figure 1)

Read more

Summary

Introduction

Notch is a trans-membrane protein with four family members (Notch 1–4). Canonical Notch signaling is initiated by interaction of the Notch protein with a cell bound ligand (Delta-like 1, 3, 4 or Jagged 1, 2) and results in cleavage of Notch, initially by ADAM10 and ADAM17 proteases, followed by cleavage by the gamma-secretase complex [1,2,3]. We will examine the current data demonstrating a non-canonical role for Notch signaling in both cancer and the immune system and suggest a better understanding of non-canonical signaling may reveal novel strategies to block Notch signaling in disease. Many instances of non-canonical signaling are associated with potentially pathological conditions including cancer and activation of the immune system while many normal cellular processes require canonical Notch signaling.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call